NasdaqGS - Delayed Quote • USD
Prelude Therapeutics Incorporated (PRLD)
At close: May 17 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | -0.42 | -0.42 | -1.68 | -1.42 |
| Low Estimate | -0.46 | -0.46 | -1.84 | -1.86 |
| High Estimate | -0.39 | -0.37 | -1.54 | -0.99 |
| Year Ago EPS | -0.54 | -0.45 | -2.02 | -1.68 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 3 | 3 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.63 | -0.58 | -0.49 | -0.48 |
| EPS Actual | -0.54 | -0.45 | -0.46 | -0.42 |
| Difference | 0.09 | 0.13 | 0.03 | 0.06 |
| Surprise % | 14.30% | 22.40% | 6.10% | 12.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.42 | -0.42 | -1.68 | -1.42 |
| 7 Days Ago | -0.43 | -0.43 | -1.72 | -1.42 |
| 30 Days Ago | -0.49 | -0.51 | -2 | -1.62 |
| 60 Days Ago | -0.49 | -0.51 | -2 | -1.62 |
| 90 Days Ago | -0.36 | -0.37 | -1.46 | -1.48 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 3 | 3 | 3 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | PRLD | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 22.20% | -- | -- | 8.00% |
| Next Qtr. | 6.70% | -- | -- | 12.40% |
| Current Year | 16.80% | -- | -- | 5.60% |
| Next Year | 15.50% | -- | -- | 12.60% |
| Next 5 Years (per annum) | 30.10% | -- | -- | 11.14% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Initiated | JMP Securities: Market Outperform | 3/13/2024 |
| Downgrade | HC Wainwright & Co.: Buy to Neutral | 2/20/2024 |
| Downgrade | Morgan Stanley: Equal-Weight to Underweight | 12/19/2023 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 11/7/2023 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 10/19/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/17/2023 |
Related Tickers
FHTX Foghorn Therapeutics Inc.
5.51
-5.16%
PMVP PMV Pharmaceuticals, Inc.
2.1000
-2.33%
IMCR Immunocore Holdings plc
53.29
-1.77%
ORIC ORIC Pharmaceuticals, Inc.
9.16
+1.55%
BCYC Bicycle Therapeutics plc
21.36
-3.70%
RPTX Repare Therapeutics Inc.
3.5500
+0.57%
PLRX Pliant Therapeutics, Inc.
15.27
-2.18%
VIGL Vigil Neuroscience, Inc.
3.5200
-0.56%
LVTX LAVA Therapeutics N.V.
2.6400
-4.35%
IPSC Century Therapeutics, Inc.
3.0100
-3.83%